A 100 years since discovery, insulin inequity continues to be a problem

Jyothi Datta writes for The Hindu BusinessLine about the Access to Medicine Foundation's report titled "What are pharma companies doing to expand access to insulin - and how can efforts be scaled up?"

Jyothi spoke to Claudia Martínez, Research Programme Manager:

"Less than 30 per cent of low- and middle-income countries currently have access to all insulins deemed essential, with the cost of insulin being a huge barrier to access. Insulin products, particularly analogue insulins, need to become affordable to every payer. Tapping into the promising potential of biosimilar insulins, for example, could expand affordability and access."